thymalfasin raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-03-13 and is reviewed periodically as new material appears.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
The activity of this peptide is generally described as immunomodulatory rather than directly antimicrobial. Experimental work links it to signaling through certain Toll-like receptors on dendritic cells and to downstream maturation of antigen-presenting cells. Reported effects include expansion of T cell subsets, shifts in cytokine profiles, and increased natural killer cell activity. These observations come largely from cell culture and animal models, and the precise receptor-level events in humans remain incompletely characterized.
The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.
| Property | Value | Notes |
|---|---|---|
| Amino acid length | 28 residues | Single chain with an acetylated N-terminus |
| Molecular mass | Approximately 3,108 Da | Small shifts occur with counter-ion and water content |
| Isoelectric point | Around 3.5 | Low value follows from the many acidic residues |
| Parent molecule | N-terminal region of prothymosin alpha | Free circulating form in humans is not firmly established |
| Common synonyms | Thymalfasin; T alpha 1 | Older literature also uses the full spelled-out form |
To prevent the entrance of individuals who are either undesirable (e.g., criminals or others who pose threats) or simply unauthorised to enter. To prevent the entrance of goods or contaminants that are illegal or subject to restriction, or to collect tariffs in accordance with customs or quarantine policies. A border checkpoint at which travellers are permitted to enter a jurisdiction is known as a port of entry. International airports are usually ports of entry, as are road and rail crossings on a land border. Seaports can be used as ports of entry only if a dedicated customs presence is posted there. The decision to become a port of entry is up to the civil authority controlling the port. An airport of entry is an airport that provides customs and immigration services for incoming flights. These services allow the airport to serve as an initial port of entry for foreign visitors arriving in the country. While the terms airport of entry and international airport are generally used interchangeably, not all international airports qualify as airports of entry, since some international airports lack immigration or customs facilities in the Schengen Area, where member states have eliminated border controls with one another. Airports of entry are usually larger than domestic airports and often feature longer runways and facilities to accommodate the heavier aircraft commonly used for international and intercontinental travel. International airports often also serve domestic flights, which help feed both passengers and cargo into international flights (and vice versa).
nucleoplasm Also karyoplasm. All of the material enclosed within the nucleus of a cell by the nuclear envelope, analogous to the cytoplasm enclosed by the main cell membrane. Like the cytoplasm, the nucleoplasm is composed of a gel-like substance (the nucleosol) in which various organelles, nuclear proteins, and other biomolecules are suspended, including nuclear DNA in the form of chromosomes, the nucleolus, nuclear bodies, and free nucleotides.
Most polyphenols are metabolized by catechol-O-methyltransferase, and therefore do not have the chemical structure allowing antioxidant activity in vivo; they may exert biological activity as signaling molecules.
Sources: en.wikipedia.org
== Causes == SJS is thought to arise from a disorder of the immune system. The immune reaction can be triggered by drugs or infections. Genetic factors are associated with a predisposition to SJS such as individuals expressing the human leukocyte antigen (i.e. HLA) serotypes HLA-B15:02 or HLA-A31:01 The cause of SJS is unknown in one-quarter to one-half of cases. SJS, SJS/TEN, and TEN are considered a single disease with common causes and mechanisms. Individuals with variations in their efficiency to absorb, distribute to tissues, metabolize, or excrete a drug are predisposed to develop SJS.
=== Acute === Acute exposure to cadmium fumes may cause flu-like symptoms including chills, fever, and muscle ache sometimes referred to as "the cadmium blues." Symptoms may resolve after a week if there is no respiratory damage. More severe exposures can cause tracheobronchitis, pneumonitis, and pulmonary edema. Symptoms of inflammation may start hours after the exposure and include cough, dryness and irritation of the nose and throat, headache, dizziness, weakness, fever, chills, and chest pain.
are the photobleaching decay time constants of the donor in the presence and in the absence of the acceptor respectively. (Notice that the fraction is the reciprocal of that used for lifetime measurements). This technique was introduced by Jovin in 1989. Its use of an entire curve of points to extract the time constants can give it accuracy advantages over the other methods. Also, the fact that time measurements are over seconds rather than nanoseconds makes it easier than fluorescence lifetime measurements, and because photobleaching decay rates do not generally depend on donor concentration (unless acceptor saturation is an issue), the careful control of concentrations needed for intensity measurements is not needed. It is, however, important to keep the illumination the same for the with- and without-acceptor measurements, as photobleaching increases markedly with more intense incident light.
Sources: en.wikipedia.org
==== United States ==== Diazepam is controlled as a Schedule IV substance. The states of California and Florida offer diazepam to condemned inmates as a pre-execution sedative as part of their lethal injection program. The state of California has not executed a prisoner since 2006. In August 2018, Nebraska used diazepam as part of the drug combination used to execute Carey Dean Moore, the first death row inmate executed in Nebraska in over 21 years.
Pegcetacoplan, sold under the brand name Empaveli among others, is a medication used to treat paroxysmal nocturnal hemoglobinuria, geographic atrophy of the retina, glomerulopathy C3 and membranoproliferative globulonephritis. Pegcetacoplan is a complement inhibitor. The most common side effects include injection-site reactions, infections, diarrhea, abdominal pain, respiratory tract infection, viral infection, and fatigue. Paroxysmal nocturnal hemoglobinuria is characterized by red blood cell destruction, anemia (red blood cells unable to carry enough oxygen to tissues), blood clots, and impaired bone marrow function (not making enough blood cells). Pegcetacoplan is the first treatment for paroxysmal nocturnal hemoglobinuria that binds to and inhibits complement protein C3. Pegcetacoplan was approved for medical use in the United States in May 2021. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication. In 2024, the American Society of Nephrology Annual Kidney Meeting, the study group who investigating pegcetacoplan in the largest multicenter double-blind VALIANT trial, showed its significant benefits in the treatment of patients with C3 glomerulopathy or primary immune complex–mediated membranoproliferative glomerulonephritis. C3 glomerulopathy leads to kidney failure in approximately 50% of patients within 5–10 years of diagnosis, and even when patients do receive a kidney transplant, approximately two thirds experience disease recurrence.
1 February – Billy Galligan, 86, hurler (Charleville, Blackrock, Claughaun, Avondhu, Cork senior team). 6 February – Niamh Bhreathnach, 77, politician, TD (1992–1997), Minister for Education (1993–1994 and 1994–1997). 7 February – Richard Kell, 95, poet, composer and teacher. 11 February – Séamus Ryan, hurler (Cappamore, Limerick senior team). 12 February James Flynn, 57, film and television producer (Vikings, The Last Duel, The Banshees of Inisherin). Theo Dunne, 85, footballer (Shelbourne) and manager (UCD). 13 February – Deirdre Purcell, 77, actress, journalist, broadcaster and author. 18 February – David G. O'Connell, 69, Roman Catholic prelate, Auxiliary Bishop of Los Angeles (2015–2023). 22 February Mick Burns, 85, hurler (Nenagh Éire Óg, Tipperary senior team, Munster). Dermot Kelly, 90, hurler (Claughaun, Limerick senior team, Munster). 24 February – Tom Tierney, 46, rugby union player (Garryowen, Munster, Leicester, national team) and coach (women's national team). 26 February Tony O'Donoghue, 86, athlete and broadcaster. Kieron Wood, 73, barrister, journalist and writer. 28 February Brian O'Brien, 83, rugby union player (Shannon, Munster, national team) and manager (Shannon, Munster, national team). Jimmy Hatton, 88, Gaelic footballer and hurler (Kilcoole, Wicklow senior teams) and referee.
Sources: en.wikipedia.org
It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.
Prothymosin alpha is a much larger acidic protein, roughly 111 to 113 residues long, and the thymosin alpha-1 sequence matches its N-terminal region. The small peptide is therefore best understood as a fragment of that parent protein rather than a separate gene product.
Trials and clinical reports have examined chronic hepatitis B and C, use as a vaccine adjuvant, and supportive treatment in some immunodeficiency and oncology settings. Results vary by indication, and regulatory approval differs between countries.
It is usually classified as an immunomodulatory peptide rather than a classical hormone. It derives from the larger protein prothymosin alpha and acts mainly on immune cells. The thymosin label covers a group of distinct peptides, so the naming can be misleading.